Lomb

Bausch + Lomb is a leading global eye health company with a legacy dating back to 1853. The company operates across three primary segments: Vision Care, which includes contact lenses and lens care products; Surgical, featuring intraocular lenses and surgical equipment; and Pharmaceuticals, which develops and markets prescription and over-the-counter ophthalmic treatments. Bausch + Lomb's pharmaceutical portfolio is anchored by key products like Xiidra for dry eye disease and Vyzulta for glaucoma. The company is actively expanding its clinical pipeline through strategic acquisitions, such as Whitecap Biosciences, and innovative partnerships, including a collaboration with City Therapeutics to develop RNAi-based therapies for geographic atrophy.